EP1019427A4 - N?6 -substitues-adenosine-5'-uronamides utiles comme modulateurs de recepteurs d'adenosine - Google Patents

N?6 -substitues-adenosine-5'-uronamides utiles comme modulateurs de recepteurs d'adenosine

Info

Publication number
EP1019427A4
EP1019427A4 EP98939156A EP98939156A EP1019427A4 EP 1019427 A4 EP1019427 A4 EP 1019427A4 EP 98939156 A EP98939156 A EP 98939156A EP 98939156 A EP98939156 A EP 98939156A EP 1019427 A4 EP1019427 A4 EP 1019427A4
Authority
EP
European Patent Office
Prior art keywords
adenosine
uronamides
substituted
receptor modulators
adenosine receptor
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP98939156A
Other languages
German (de)
English (en)
Other versions
EP1019427A1 (fr
Inventor
Pier G Baraldi
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
MedCo Research Inc
Original Assignee
MedCo Research Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by MedCo Research Inc filed Critical MedCo Research Inc
Publication of EP1019427A4 publication Critical patent/EP1019427A4/fr
Publication of EP1019427A1 publication Critical patent/EP1019427A1/fr
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/16—Purine radicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/16—Central respiratory analeptics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Cardiology (AREA)
  • Neurology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Ophthalmology & Optometry (AREA)
  • Vascular Medicine (AREA)
  • Obesity (AREA)
  • Pulmonology (AREA)
  • Hospice & Palliative Care (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Psychiatry (AREA)
  • Urology & Nephrology (AREA)
  • Rheumatology (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
EP98939156A 1997-07-29 1998-07-29 N?6 -substitues-adenosine-5'-uronamides utiles comme modulateurs de recepteurs d'adenosine Withdrawn EP1019427A1 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US5406497P 1997-07-29 1997-07-29
US54064P 1997-07-29
PCT/US1998/016053 WO1999006053A1 (fr) 1997-07-29 1998-07-29 N6-substitues-adenosine-5'-uronamides utiles comme modulateurs de recepteurs d'adenosine

Publications (2)

Publication Number Publication Date
EP1019427A4 true EP1019427A4 (fr) 2000-07-19
EP1019427A1 EP1019427A1 (fr) 2000-07-19

Family

ID=21988552

Family Applications (1)

Application Number Title Priority Date Filing Date
EP98939156A Withdrawn EP1019427A1 (fr) 1997-07-29 1998-07-29 N?6 -substitues-adenosine-5'-uronamides utiles comme modulateurs de recepteurs d'adenosine

Country Status (5)

Country Link
EP (1) EP1019427A1 (fr)
JP (1) JP2003517423A (fr)
AU (1) AU8764398A (fr)
CA (1) CA2296485A1 (fr)
WO (1) WO1999006053A1 (fr)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0991414A4 (fr) * 1997-05-09 2002-10-02 Univ Pennsylvania Methodes visant a reduire une lesion ischemique cardiaque par administration d'agonistes et d'antagonistes du recepteur d'adenosine et compositions afferentes
US6878716B1 (en) 1998-06-02 2005-04-12 Osi Pharmaceuticals, Inc. Compounds specific to adenosine A1 receptor and uses thereof
BR9911612A (pt) 1998-06-02 2001-02-06 Osi Pharm Inc Composições de pirrolo[2,3d]pirimidina e seus usos
US6686366B1 (en) 1998-06-02 2004-02-03 Osi Pharmaceuticals, Inc. Compounds specific to adenosine A3 receptor and uses thereof
IL133680A0 (en) * 1999-09-10 2001-04-30 Can Fite Technologies Ltd Pharmaceutical compositions comprising an adenosine receptor agonist or antagonist
US6680322B2 (en) 1999-12-02 2004-01-20 Osi Pharmaceuticals, Inc. Compounds specific to adenosine A1 receptors and uses thereof
US7160890B2 (en) 1999-12-02 2007-01-09 Osi Pharmaceuticals, Inc. Compounds specific to adenosine A3 receptor and uses thereof
PT1246623E (pt) 1999-12-02 2006-12-29 Osi Pharm Inc Compostos específicos para o receptor de adenosina a1,a2a e a3 e as suas utilizações
US6664252B2 (en) 1999-12-02 2003-12-16 Osi Pharmaceuticals, Inc. 4-aminopyrrolo[2,3-d]pyrimidine compounds specific to adenosine A2a receptor and uses thereof
AU2002211142A1 (en) * 2000-10-26 2002-05-06 Actar Ab Screening method using a g coupled receptor associated with a specific g protein
US6680324B2 (en) 2000-12-01 2004-01-20 Osi Pharmaceuticals, Inc. Compounds specific to adenosine A1 receptors and uses thereof
US6673802B2 (en) 2000-12-01 2004-01-06 Osi Pharmaceuticals, Inc. Compounds specific to adenosine A3 receptor and uses thereof
US7589075B2 (en) 2001-01-16 2009-09-15 Can-Fite Biopharma Ltd. Use of an adenosine A3 receptor agonist for inhibition of viral replication
US20020115635A1 (en) * 2001-02-21 2002-08-22 Pnina Fishman Modulation of GSK-3beta activity and its different uses
WO2003048120A2 (fr) 2001-11-30 2003-06-12 Osi Pharmaceuticals, Inc. Composes specifiques des recepteurs a1 et a3 de l'adenosine et leurs utilisations
WO2003053366A2 (fr) 2001-12-20 2003-07-03 Osi Pharmaceuticals, Inc. Composes pyrimidine antagonistes selectifs des recepteurs a2b, leur synthese et leur utilisation
US20030229067A1 (en) 2001-12-20 2003-12-11 Arlindo Castelhano Pyrrolopyrimidine A2b selective antagonist compounds, their synthesis and use
GB0228723D0 (en) 2002-12-09 2003-01-15 Cambridge Biotechnology Ltd Treatment of pain
US7749981B2 (en) 2003-10-21 2010-07-06 Inspire Pharmaceuticals, Inc. Drug-eluting stents coated with non-nucleotide P2Y12 receptor antagonist compound
EP1685135B1 (fr) 2003-10-21 2010-05-26 Inspire Pharmaceuticals, Inc. COMPOSES TETRAHYDRO-FURO[3,4-d]DIOXOLE, ET COMPOSITIONS ET PROCEDE POUR INHIBER UNE AGREGATION PLAQUETTAIRE
US7335648B2 (en) 2003-10-21 2008-02-26 Inspire Pharmaceuticals, Inc. Non-nucleotide composition and method for inhibiting platelet aggregation
US7825102B2 (en) 2004-07-28 2010-11-02 Can-Fite Biopharma Ltd. Treatment of dry eye conditions
ES2432113T3 (es) * 2004-07-28 2013-11-29 Can-Fite Biopharma Ltd. Agonistas del receptor de adenosina A3 para el tratamiento de trastornos del ojo seco, incluido el síndrome de Sjogren
EP1798233A1 (fr) * 2005-12-19 2007-06-20 Faust Pharmaceuticals Dérivés de Pyrrolo[1,2-a]quinoxaline et leur utilisation comme modulateurs de recepteurs a l'adenosine
ES2490606T3 (es) 2007-10-15 2014-09-04 Can-Fite Biopharma Ltd. Procedimiento para inducir proliferación de hepatocitos y usos del mismo
JP5849044B2 (ja) 2009-05-17 2016-01-27 キャン−ファイト バイオファーマ リミテッド 眼圧低下のためのａ３アデノシン受容体作動薬
EP2456419B1 (fr) 2009-07-21 2016-11-23 Oradin Pharmaceutical Ltd. Ligands du récepteur a3 adenosine pour la modulation de la pigmentation
US20130045943A1 (en) 2010-03-03 2013-02-21 The Government Of The United States Of America As Represented By The Secretary Of The Department Of A3ar agonists for the treatment of uveitis
BR112015002697A8 (pt) 2012-08-09 2018-01-16 Can Fite Biopharma Ltd uso de ligante de receptor de adenosina a3 (a3ar), ligante de a3ar, e, composição farmacêutica para tratar disfunção sexual em um indivíduo
IL242723B (en) 2015-11-23 2019-12-31 Can Fite Biopharma Ltd A3 adenosine receptor ligand for the treatment of ectopic fat accumulation
IL254535A0 (en) 2017-09-17 2017-11-30 Can Fite Biopharma Ltd Adenosine a3 receptor ligand for use in the management of cytokine release syndrome
IL264112A (en) 2019-01-06 2020-07-30 Fishman Pnina Adenosine a3 receptor ligand for use in lowering adipocyte levels

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998050047A1 (fr) * 1997-05-09 1998-11-12 Trustees Of The University Of Pennsylvania Methodes visant a reduire une lesion ischemique cardiaque par administration d'agonistes et d'antagonistes du recepteur d'adenosine et compositions afferentes

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5310731A (en) * 1984-06-28 1994-05-10 Whitby Research, Inc. N-6 substituted-5'-(N-substitutedcarboxamido)adenosines as cardiac vasodilators and antihypertensive agents

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998050047A1 (fr) * 1997-05-09 1998-11-12 Trustees Of The University Of Pennsylvania Methodes visant a reduire une lesion ischemique cardiaque par administration d'agonistes et d'antagonistes du recepteur d'adenosine et compositions afferentes

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
C.GALLO-RODRIGUEZ ET AL.: "Structure Activity Relationships of N6-Benzyladenosine-5'-uronamides as A3 Selective Adenosine Agonists.", JOURNAL OF MEDICINAL CHEMISTRY., vol. 37, no. 5, 4 March 1994 (1994-03-04), AMERICAN CHEMICAL SOCIETY. WASHINGTON., US, pages 636 - 646, XP002136400, ISSN: 0022-2623 *
H.O.KIM ET AL.: "2-Substitution of N6-Benzoyladenosine-5'-Uronamides Enhances Selectivity for A3 Adenosine Receptors.", JOURNAL OF MEDICINAL CHEMISTRY., vol. 37, no. 21, 14 October 1994 (1994-10-14), AMERICAN CHEMICAL SOCIETY. WASHINGTON., US, pages 3614 - 3621, XP002136401, ISSN: 0022-2623 *
See also references of WO9906053A1 *

Also Published As

Publication number Publication date
JP2003517423A (ja) 2003-05-27
EP1019427A1 (fr) 2000-07-19
WO1999006053A1 (fr) 1999-02-11
CA2296485A1 (fr) 1999-02-11
AU8764398A (en) 1999-02-22

Similar Documents

Publication Publication Date Title
EP1019427A4 (fr) N?6 -substitues-adenosine-5'-uronamides utiles comme modulateurs de recepteurs d'adenosine
GB2353527B (en) Adenosine A3 receptor modulators
GB9715751D0 (en) Formulations
HUP0100536A3 (en) Fiber distributor
HU9601529D0 (en) Pyrimidinedion-, pyrimidinetrion-, triazinedion-, tetrahydro-quinazolinedion- derivatives as alpha-adrenerg receptor antagonists
EP0996458A4 (fr) Analogues de sandramycine
IL133920A0 (en) Trail receptor
AU7132898A (en) Edg-1-like receptor
GB9517098D0 (en) Receptor
GB9617923D0 (en) Novel receptor
EP0973800A4 (fr) Nouveau recepteur
GB2321753B (en) Metering system
GB9701050D0 (en) Structural member
PL340723A1 (en) Structural member
GB9515669D0 (en) Releasable fixing means
GB9425502D0 (en) Novel receptor
ZA987267B (en) Nucleosides
IL139493A0 (en) Adenosine a3 receptor modulators
IL156851A0 (en) Adenosine a3 receptor modulators
GB9703676D0 (en) Stable system
GB9810606D0 (en) Distributor units
HU0002453D0 (en) Novel nucleosides
CA81596S (en) Structural member
AU133746S (en) Distributor
AUPO910797A0 (en) Receptor

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20000202

A4 Supplementary search report drawn up and despatched

Effective date: 20000606

AK Designated contracting states

Kind code of ref document: A4

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE

Kind code of ref document: A1

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE

17Q First examination report despatched

Effective date: 20010330

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20011010